Bayer to develop NGS based companion diagnostics in oncology

image credit- clpmag.com

Bayer AG and Foundation Medicine, Inc. have announced a global collaboration for the development and commercialization of NGS-based companion diagnostics.

This agreement allows for collaboration across multiple oncology drug candidates and approved therapies developed by Bayer and covers Foundation Medicine’s full portfolio of tests, including FoundationOne^®CDx.

The first project will be to develop a companion diagnostic for larotrectinib, the first and only TRK inhibitor approved in the U.S. for patients with TRK fusion cancer across all solid tumors. 

NGS-based companion diagnostic tests aim to unlock molecular information from each patient’s tumor genome to guide treatment decisions for cancer therapies.

FoundationOne^®CDx is the first FDA-approved broad companion diagnostic for all solid tumors.